Garry E. Menzel, President & CEO at TCR2 THERAPEUTICS INC. (TCRR), sold 8,408 shares at $1.39 ($12K) on 2022-12-02, disclosed to the SEC on 2022-12-05.
Scheduled sale ($12k) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| TCRR | SELL | 2022-12-09 | $23K | — | Filing → |
| TCRR | SELL | 2022-12-07 | $32K | — | Filing → |